ELISE SPLIT: Open Payments
NPI 1467417063 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,058 in 39 payments from 13 companies in 2025. Trend: 2023 $1,251 · 2024 $947 · 2025 $1,058
Food & beverage: $1,058
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $274 |
| Edwards Lifesciences Corporation | 2 | $218 |
| Alnylam Pharmaceuticals Inc. | 7 | $201 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53 |
| Novartis Pharmaceuticals Corporation | 3 | $53 |
| Novo Nordisk Inc | 2 | $37 |
| Philips North America LLC | 1 | $29 |
| SCPHARMACEUTICALS INC. | 2 | $29 |
| Amgen Inc. | 2 | $29 |
Products named: CAMZYOS, PASCAL, AMVUTTRA, NEXLETOL, JARDIANCE, LEQVIO, Ambulatory Monitoring & Diagnostics Undivided, FUROSCIX.
Industry payments across AL — which companies pay providers there.
